Form 4: Glaukos Corp CEO Thomas Burns Reports Stock Transactions

Thomas Burns, Chairman and CEO of Glaukos Corporation, reports acquisition and disposal of company stock and derivative securities.

Summary

• Thomas Burns, the Chairman and CEO of Glaukos Corporation, filed a Form 4 detailing changes in his beneficial ownership of Glaukos stock.
• On March 13, 2025, Burns acquired shares of common stock underlying restricted stock units (RSUs) from previous grants due to the achievement of operational targets.
• He acquired 15,418 shares from a March 18, 2021 grant, 14,183 shares from a March 14, 2024 grant, 15,113 shares from an April 1, 2024 grant related to a bonus election, and 39,596 shares from another grant vesting over four years.
• Burns also acquired 24,102 stock options with an exercise price of $96.60, vesting over four years from March 13, 2025.
• On March 17, 2025, 2,013 shares were withheld by the issuer for tax obligations related to the vesting of RSUs from a March 14, 2024 grant.
• Following these transactions, Burns directly owns 168,155 shares of common stock and indirectly owns shares through various trusts.
• He also directly owns 24,102 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The document primarily reflects routine insider transactions related to executive compensation. The achievement of operational targets is a positive sign, but the overall impact is neutral to slightly positive.

Positives

• The vesting of RSUs indicates that Glaukos Corporation has achieved certain operational targets, which could be viewed positively by investors.
• The CEO's acquisition of stock options could be interpreted as a sign of confidence in the company's future performance.
• The CEO's continued holding of a significant number of shares, both directly and indirectly, demonstrates a long-term commitment to the company.

Negatives

• The withholding of shares for tax obligations could be seen as a minor negative, as it reduces the number of shares directly held by the CEO.

Risks

• The vesting of RSUs is contingent upon continued employment, so any change in the CEO's employment status could affect the vesting schedule.
• The value of the stock options is dependent on the future stock price, so there is a risk that they may not be valuable if the stock price does not increase.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of RSUs based on operational targets suggests an expectation of continued performance.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's confidence in the company's prospects. The vesting of RSUs due to the achievement of operational targets could be seen as a positive signal for Glaukos.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in the pharmaceutical and medical device industries.
• Companies like Alcon, Johnson & Johnson, and Bausch + Lomb also utilize similar equity-based compensation plans to align executive incentives with shareholder value.
• The vesting schedules and performance-based criteria for these awards are generally aligned with industry best practices.

Stakeholder Impact

• The vesting of RSUs and the granting of stock options align management's interests with those of shareholders.
• The achievement of operational targets could lead to improved financial performance, benefiting shareholders, employees, and other stakeholders.

Next Steps

• Continued monitoring of insider transactions to gauge management's sentiment and confidence in the company.
• Tracking the vesting of RSUs and the exercise of stock options to understand the potential impact on the company's share structure.

Key Dates